Overblog
Edit post Seguir este blog Administration + Create my blog
10 febrero 2015 2 10 /02 /febrero /2015 20:06


"Biomarker-guided patient selection strategies have already contributed to positive outcomes in clinical trials for new candidate therapies for asthma. As I will discuss at the conference, recent successes with antibodies targeting interleukin (IL-)5, IL-13 and related type 2 inflammatory pathways have demonstrated the value of using predictive biomarkers to select patients most likely to benefit." (DR JOSEPH ARRON Biomarker & Discovery, Genentech Inc)

 

 

Asthma & COPD 2015: Genentech proporcionar una nueva perspectiva de la terapia dirigida al asma grave

Asthma & COPD 2015 proporcionará información progresiva de la evolución reciente y futuro de la terapéutica, del diagnóstico y atención en el ámbito respiratorio. El evento contará con presentaciones de 20 casos de estudio, contará con oradores en representación de la industria y la academia, un taller interactivo, una mesa redonda, y más de 3 horas de trabajo en red.

Destaca en el evento una conferencia del Dr. Joseph Arron Director Asociado de Genentech. La charla tratará la heterogeneidad del asma, la hipótesis de la selección de biomarcadores y nuevos desarrollos en los fenotipos de asma.

Hablando acerca de la conferencia, el Dr. Joseph Arron, Director Asociado de Biomarker & Discovery, Genentech Inc dijo:

"En conferencias como esta, yo siempre tengo ganas de escuchar lo que los médicos académicos están pensando - están más cercanos a los pacientes y generan conocimientos clave que nos ayudan en el desarrollo de fármacos y a pensar diferente acerca de cómo abordar la enfermedad."

El Dr Arron, que lidera un grupo de descubrimiento de biomarcadores en el laboratorio Genentech, también dijo:
"Las estrategias seleccionadas para los pacientes, guiada por biomarcadores, ya han contribuido a resultados positivos en los ensayos clínicos de nuevas terapias promisorias para el asma. Como voy a discutir en la conferencia, los éxitos recientes con anticuerpos dirigidos a la interleuquina IL -5, IL-13 y la relacionada vía inflamatoria tipo 2 han demostrado el valor de utilizar biomarcadores predictivos para seleccionar pacientes con más probabilidades de beneficiarse ".


Sobre cómo prevé el futuro del tratamiento de trastornos respiratorios, comentó:

"A medida que se desarrollan las terapias moleculares, necesitamos alejarnos de algoritmos de tratamiento basados en síntomas empíricos, orientándonos hacia herramientas de toma de decisiones biológicamente informadas. Lo ideal es que si somos capaces de tratar con éxito un subtipo de asma y enfermedad obstructiva pulmonar crónica (Chronic Obstructive Pulmonary Disease COPD) podemos centrar nuestros esfuerzos en la identificación de nuevas dianas terapéuticas en los subtipos que no se benefician de estas intervenciones ".


To read the full interview visit the download page at http://www.smi-online.co.uk/goto/2015asthma-copd38.asp

 

-------------------------

 

Asthma & COPD 2015: Genentech to provide a new perspective on targeted therapy for severe asthma

Asthma & COPD 2015: Genentech proporcionar una nueva perspectiva de la terapia dirigida al asma grave

SMi’s 11th annual Asthma & COPD conference will be taking place on the 13th-14th April 2015 in London, UK.

LONDON, ENGLAND, UNITED KINGDOM, February 10, 2015 /EINPresswire.com/ -- Genentech will provide a new perspective on targeted therapy for severe asthma at the upcoming Asthma & COPD conference, taking place for the 11th year on the 13th-14th April in London, UK.

Asthma & COPD 2015 will provide progressive insights into recent developments and explore the future of therapeutics, diagnosis and care in the respiratory arena. The event will feature over 20 case study driven presentations, speakers representing both industry and academia, an interactive workshop, a round table discussion, plus over 3 hours of networking.

Highlights of the event will include an address from Genentech Associate Director, Dr Joseph Arron. The talk will discuss asthma heterogeneity, biomarker selection hypothesis and new developments into asthma phenotypes.

Speaking about the conference, Dr Joseph Arron, Associate Director - Biomarker & Discovery, Genentech Inc said:

"At conferences like this, I always look forward to hearing what academic clinicians are thinking about - they are closest to the patients and generate key insights that help those of us in drug development think differently about how to approach disease."

Dr Arron, who leads a laboratory-based biomarker discovery group at Genentech, also said:

"Biomarker-guided patient selection strategies have already contributed to positive outcomes in clinical trials for new candidate therapies for asthma. As I will discuss at the conference, recent successes with antibodies targeting interleukin (IL-)5, IL-13 and related type 2 inflammatory pathways have demonstrated the value of using predictive biomarkers to select patients most likely to benefit."

On how he envisioned the future of respiratory disorder treatment, he commented:

"As more highly targeted molecular therapies are developed, we need to move away from empirical symptom-based treatment algorithms toward biologically-informed decision-making tools. Ideally, if we are able to successfully treat one subtype of asthma and/or COPD we can focus our efforts on identifying new therapeutic targets in the subtypes that do not benefit from these interventions."

To read the full interview visit the download page at http://www.smi-online.co.uk/goto/2015asthma-copd38.asp

Asthma and COPD 2015: Exploring the future of therapeutics, diagnosis and care, 13 - 14 April 2015 Holiday Inn Regents Pak Hotel, London UKAsthma and COPD 2015: Exploring the future of therapeutics, diagnosis and care, 13 - 14 April 2015 Holiday Inn Regents Pak Hotel, London UKAsthma and COPD 2015: Exploring the future of therapeutics, diagnosis and care, 13 - 14 April 2015 Holiday Inn Regents Pak Hotel, London UK

 

 

Set to take place on 13th and 14th April, SMI’s sell-out Asthma & COPD conference returns to London next spring for its 11th annual show. With the global market for asthma and COPD drugs set to reach $41.23bn in 2017, Asthma & COPD 2015 comes at the perfect time to explore the future of therapeutics, diagnosis and care.

We have worked closely with a leading panel of experts such as Genentech, GSK, MedImmune, Amgen and Imperial College of London, to create an agenda that will provide unique insights into topics such as lab to clinic pathways, personalised care, viruses in asthma and COPD, future advancements, PLUS MUCH MORE

Join us we ask questions such as: How is severe asthma in children pathophysiologically different to the adult disease? Is airway remodelling dependent on inflammation? What value can patient charities bring to multi-partner collaborations? What are the drug development challenges associated with inhaled and intranasal antivirals? What are the key areas of unmet clinical needs for COPD clinical care?

REASONS TO ATTEND
•    Explore the future of asthma and COPD treatment from a range of key perspectives
•    Discover advances in inhaled therapies
•    Discuss personalised therapy approaches, asthma patient stratification and unmet needs
•    Share in the latest thinking from the clinic to improve the lives of patients
•    Explore the latest thinking on biomarkers and clinical trial endpoints
•    Update on mechanisms and treatment for viral induced COPD and asthma exacerbations

KEY SPEAKERS INCLUDE:
•    Sebastian Johnston, Professor of Respiratory Medicine, National Heart and Lung Institute, Imperial College London – Conference Chair
•    Robert Niven, Senior Lecturer in Respiratory Medicine, Manchester University – Conference Chair
•    Neil C Thomson, Professor of Respiratory Medicine, University of Glasgow
•    Joseph Arron, Associate Director, Biomarker Discovery, Genentech, Inc.
•    Dirk Smith, Scientific Director, Amgen
•    U Roland Kolbeck, Senior Director, Respiratory, Inflammation & Autoimmunity, MedImmune
•    Hector Ortega, Medical Director, Respiratory R&D, GSK
•    Maria Buxton, Consultant Respiratory Physiotherapist, London North West Healthcare NHS Trust

SMi Group has been at the forefront of respiratory conferences for over a decade. Comments from previous instalments in the established series include: “Excellent, both days” – Prosonix, “Good Networking opportunities” – Novartis and “Good level of speaker expertise, worthwhile to attend” Biomedical systems

For further information and to secure your place, visit: www.asthma-copd.co.uk

 

http://www.labsave.com/events/295-asthma-and-copd-2015-exploring-the-future-of-therapeutics-diagnosis-and-care-13-14-april-2015-holiday-inn-regents-pak-hotel-london-uk

 

 

Compartir este post

Repost0

Comentarios

Présenta

  • : cinabrio blog
  • : Ecología y sostenibilidad socioambiental, énfasis en conservación de ríos y ecosistemas, denuncia de impacto de megaproyectos. Todo esto es indesligable de la política y por ello esta también se observa. Ecology, social and environmental sustainability, emphasis on conservation of rivers and ecosystems, denounces impact of megaprojects. All this is inseparable from politics, for it, the politics is also evaluated.
  • Contacto

Perfil

  • Malcolm Allison H malcolm.mallison@gmail.com
  • Biólogo desde hace más de treinta años, desde la época en que aún los biólogos no eran empleados de los abogados ambientalistas. Actualmente preocupado …alarmado en realidad, por el LESIVO TRATADO DE(DES)INTEGRACIÓN ENERGÉTICA CON BRASIL
  • Biólogo desde hace más de treinta años, desde la época en que aún los biólogos no eran empleados de los abogados ambientalistas. Actualmente preocupado …alarmado en realidad, por el LESIVO TRATADO DE(DES)INTEGRACIÓN ENERGÉTICA CON BRASIL

Recherche

Liens